{"page":{"totalFilteredElements":344},"studies":[{"active":true,"description":"<div>ALL SCT FORUM Registry 2022</div><div>Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia</div>","eudractNumber":null,"id":9804,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2024-10-01T08:39:44+02:00","shortTitle":"ALL SCT FORUM Registry 2022","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Beobachtungsstudie und Biobank f&#252;r Rezidive einer akuten lymphoblastischen Leuk&#228;mie im Kindes- und Jugendalter<br />","eudractNumber":null,"id":656,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2012-10-01T09:06:33+02:00","shortTitle":"ALL- REZ BFM","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"ALL-BFM-Register zur Erfassung von Daten von Kindern und Jugendlichen mit akuter lymphoblastischer Leuk&#228;mie in Deutschland","eudractNumber":null,"id":10535,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2025-01-17T13:12:17+01:00","shortTitle":"ALL-BFM Register","therapeutical":true,"therapyLines":[]},{"active":true,"description":"<div>A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator&#8217;s Choice in Participants with Chemotherapy-na&#239;ve Metastatic Castration-resistant Prostate Cancer</div>","eudractNumber":"2025-520555-89","id":11331,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":"NCT07213674","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-15T10:26:05+01:00","shortTitle":"AMG 509 20230239","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter \nStudy of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell \nLung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent \nChemoradiation Therapy","eudractNumber":"2023-506235-15","id":9281,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"}],"mutations":[],"nctNumber":"NCT06117774","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-12-13T10:24:08+01:00","shortTitle":"AMG 757 20230016 (DeLLphi-306)","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)","eudractNumber":"2024-511838-12-00","id":9817,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"}],"mutations":[],"nctNumber":"NCT06598306","phase":{"id":"ph_14","name":"Phase I/IB"},"recruitmentStart":"2024-11-26T10:25:10+01:00","shortTitle":"AMG 757 20230298 (DeLLphi-308)","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A\nPhase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in\ncombination with Durvalumab, Carboplatin and Etoposide versus Durvalumab,\nCarboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer\n(DeLLphi-312)","eudractNumber":"2024-520050-38","id":10677,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"}],"mutations":[],"nctNumber":"NCT07005128","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-30T12:23:23+02:00","shortTitle":"AMG 757 20240178 (DeLLphi-312)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase 3, Open-label, Multicenter, Randomized&#160;Study of Xaluritamig vs Cabazitaxel or Second&#160;Androgen Receptor-Directed Therapy in&#160;Subjects With Metastatic Castration-Resistant&#160;Prostate Cancer Previously Treated With&#160;Chemotherapy","eudractNumber":"2024-513968-25","id":10039,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-25T09:31:19+02:00","shortTitle":"AMG509 20230005 STEAP-1","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Register AML-BFM 2017 zur Erfassung akuter myeloischer Leuk&#228;mien bei Kindern und Jugendlichen<br />","eudractNumber":null,"id":3877,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2018-04-03T14:35:25+02:00","shortTitle":"AML-BFM Register 2017","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Randomized, placebo controlled Phase III Study of Induction and Consolidation chemotherapy with Venetoclax in adult patients with newly diagnosed acute myeloid Leukemia or Myelodyspalstic syndrome with ecxess Blasts-2","eudractNumber":"2023-507518-28-00","id":11260,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT04628026","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-08-05T09:00:15+02:00","shortTitle":"AMLSG 31-19","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}